JP7401121B2 - 固形癌診断装置及び固形癌診断情報の提供方法 - Google Patents
固形癌診断装置及び固形癌診断情報の提供方法 Download PDFInfo
- Publication number
- JP7401121B2 JP7401121B2 JP2021572576A JP2021572576A JP7401121B2 JP 7401121 B2 JP7401121 B2 JP 7401121B2 JP 2021572576 A JP2021572576 A JP 2021572576A JP 2021572576 A JP2021572576 A JP 2021572576A JP 7401121 B2 JP7401121 B2 JP 7401121B2
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- concentration
- diagnosis
- diagnostic
- discriminant analysis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 206010028980 Neoplasm Diseases 0.000 title claims description 113
- 201000011510 cancer Diseases 0.000 title claims description 81
- 239000007787 solid Substances 0.000 title claims description 39
- 238000000034 method Methods 0.000 title claims description 25
- FUJLYHJROOYKRA-QGZVFWFLSA-N O-lauroyl-L-carnitine Chemical compound CCCCCCCCCCCC(=O)O[C@H](CC([O-])=O)C[N+](C)(C)C FUJLYHJROOYKRA-QGZVFWFLSA-N 0.000 claims description 51
- VVPRQWTYSNDTEA-LLVKDONJSA-N O-hexanoyl-L-carnitine Chemical compound CCCCCC(=O)O[C@H](CC([O-])=O)C[N+](C)(C)C VVPRQWTYSNDTEA-LLVKDONJSA-N 0.000 claims description 38
- 201000009036 biliary tract cancer Diseases 0.000 claims description 37
- 208000020790 biliary tract neoplasm Diseases 0.000 claims description 37
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 35
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 35
- 201000002528 pancreatic cancer Diseases 0.000 claims description 35
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 35
- 238000003745 diagnosis Methods 0.000 claims description 34
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 33
- MEFKEPWMEQBLKI-AIRLBKTGSA-O S-adenosyl-L-methionine Chemical compound O[C@@H]1[C@H](O)[C@@H](C[S+](CC[C@H]([NH3+])C([O-])=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 MEFKEPWMEQBLKI-AIRLBKTGSA-O 0.000 claims description 33
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 33
- 206010017758 gastric cancer Diseases 0.000 claims description 33
- 201000005202 lung cancer Diseases 0.000 claims description 33
- 208000020816 lung neoplasm Diseases 0.000 claims description 33
- 201000011549 stomach cancer Diseases 0.000 claims description 33
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 32
- JLQSXXWTCJPCBC-UHFFFAOYSA-N N-methyl-6-pyridone-3-carboxamide Chemical compound CN1C=C(C(N)=O)C=CC1=O JLQSXXWTCJPCBC-UHFFFAOYSA-N 0.000 claims description 32
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 32
- 201000010881 cervical cancer Diseases 0.000 claims description 32
- 238000004458 analytical method Methods 0.000 claims description 31
- 206010006187 Breast cancer Diseases 0.000 claims description 30
- 208000026310 Breast neoplasm Diseases 0.000 claims description 30
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 28
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 28
- 206010038389 Renal cancer Diseases 0.000 claims description 28
- 201000010982 kidney cancer Diseases 0.000 claims description 28
- 201000007270 liver cancer Diseases 0.000 claims description 28
- 208000014018 liver neoplasm Diseases 0.000 claims description 28
- RYCNUMLMNKHWPZ-SNVBAGLBSA-N 1-acetyl-sn-glycero-3-phosphocholine Chemical compound CC(=O)OC[C@@H](O)COP([O-])(=O)OCC[N+](C)(C)C RYCNUMLMNKHWPZ-SNVBAGLBSA-N 0.000 claims description 24
- 238000005259 measurement Methods 0.000 claims description 18
- 239000012472 biological sample Substances 0.000 claims description 17
- 238000007781 pre-processing Methods 0.000 claims description 13
- CXTATJFJDMJMIY-CYBMUJFWSA-O [(2r)-3-carboxy-2-octanoyloxypropyl]-trimethylazanium Chemical compound CCCCCCCC(=O)O[C@H](CC(O)=O)C[N+](C)(C)C CXTATJFJDMJMIY-CYBMUJFWSA-O 0.000 claims description 11
- 238000001840 matrix-assisted laser desorption--ionisation time-of-flight mass spectrometry Methods 0.000 claims description 7
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 claims description 6
- 238000004949 mass spectrometry Methods 0.000 claims description 6
- XOMRRQXKHMYMOC-OAQYLSRUSA-O [(2r)-3-carboxy-2-hexadecanoyloxypropyl]-trimethylazanium Chemical compound CCCCCCCCCCCCCCCC(=O)O[C@H](CC(O)=O)C[N+](C)(C)C XOMRRQXKHMYMOC-OAQYLSRUSA-O 0.000 claims 9
- 206010009944 Colon cancer Diseases 0.000 description 36
- CXTATJFJDMJMIY-UHFFFAOYSA-N O-octanoylcarnitine Chemical compound CCCCCCCC(=O)OC(CC([O-])=O)C[N+](C)(C)C CXTATJFJDMJMIY-UHFFFAOYSA-N 0.000 description 30
- XOMRRQXKHMYMOC-OAQYLSRUSA-N O-palmitoyl-L-carnitine Chemical compound CCCCCCCCCCCCCCCC(=O)O[C@H](CC([O-])=O)C[N+](C)(C)C XOMRRQXKHMYMOC-OAQYLSRUSA-N 0.000 description 28
- 210000004369 blood Anatomy 0.000 description 25
- 239000008280 blood Substances 0.000 description 25
- 208000029742 colonic neoplasm Diseases 0.000 description 20
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 15
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 12
- 239000003550 marker Substances 0.000 description 11
- 230000006870 function Effects 0.000 description 10
- 239000002904 solvent Substances 0.000 description 8
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 238000010586 diagram Methods 0.000 description 6
- 239000002207 metabolite Substances 0.000 description 6
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 6
- 238000012986 modification Methods 0.000 description 5
- 230000004048 modification Effects 0.000 description 5
- 238000012216 screening Methods 0.000 description 5
- 238000001574 biopsy Methods 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- 150000002500 ions Chemical class 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 239000003643 water by type Substances 0.000 description 4
- 239000000284 extract Substances 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 230000003287 optical effect Effects 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 229910001873 dinitrogen Inorganic materials 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 235000019253 formic acid Nutrition 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000004885 tandem mass spectrometry Methods 0.000 description 2
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 230000005907 cancer growth Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- 238000012606 in vitro cell culture Methods 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/62—Detectors specially adapted therefor
- G01N30/72—Mass spectrometers
- G01N30/7233—Mass spectrometers interfaced to liquid or supercritical fluid chromatograph
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57415—Specifically defined cancers of breast
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/88—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/62—Detectors specially adapted therefor
- G01N30/72—Mass spectrometers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/86—Signal analysis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57419—Specifically defined cancers of colon
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57446—Specifically defined cancers of stomach or intestine
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/88—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86
- G01N2030/8809—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample
- G01N2030/8813—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample biological materials
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/88—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86
- G01N2030/8809—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample
- G01N2030/8813—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample biological materials
- G01N2030/8818—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample biological materials involving amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/88—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86
- G01N2030/8809—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample
- G01N2030/8813—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample biological materials
- G01N2030/8822—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample biological materials involving blood
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2405/00—Assays, e.g. immunoassays or enzyme assays, involving lipids
- G01N2405/04—Phospholipids, i.e. phosphoglycerides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Bioinformatics & Computational Biology (AREA)
- Biophysics (AREA)
- Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Description
血清の確保
正常対照群36人、肺癌患者10人、胆道癌患者36人、大腸癌患者36人、膵臓癌患者36人から血清を確保した。
50μLの血清に0.95mLの水と2mLのメタノール、0.9mLのジクロロメタンを加え、振とうしながらよく混合した後、氷の上で30分間放置した。再び1mLの水と0.9mLのジクロロメタンを加え、よく混合した後、室温で10分、1,500rpmで遠心分離を行った。遠心分離後、上清を分離し、窒素ガスで乾燥させた。
乾燥された代謝体抽出物を0.1%ギ酸に溶解し後、液体クロマトグラフィー質量分析(LC-MS)を利用して分析を行った。
図2は、癌患者群と正常対照群から得られた血液中の4種のACの相対定量値(質量ピーク面積)を示したものである。HC、OC、DC、PCの血液中の相対定量値は、は質量分析計により獲得した。
血漿の確保
正常対照群、乳癌患者、胃癌患者、脳腫瘍患者、腎臓癌患者、肝癌患者、子宮頸部癌患者から血漿をそれぞれ確保した。
50μLの血漿に0.95mLの水と2mLのメタノール、0.9mLのジクロロメタンを加えて、振とうしながらよく混合した後、氷の上で30分間放置した。再び1mLの水と0.9mLのジクロロメタンを加え、よく混合した後、室温で10分、1,500rpmで遠心分離を行った。遠心分離後、上清を分離し、窒素ガスで乾燥させた。
乾燥された代謝体抽出物を0.1%ギ酸に溶解し後、液体クロマトグラフィー質量分析(LC-MS)を利用して分析を行った。
前記表11及び図4は、癌患者群と正常対照群から得られた血漿中のDC及びOCの絶対定量値を示したものである。DC及びOCの血漿中の絶対定量値は質量分析計を通じて獲得した。
Claims (18)
- 生物学的試料からアシル-カルニチン(AC)、ヌジフロラミド(2PY)及びリゾホスファチジルコリン(LPC)のそれぞれの濃度を測定する濃度測定部;
前記測定された濃度を前処理する前処理部;及び
前記前処理された濃度を用いて線形判別分析(LDA)を行うことによって、癌の診断情報を判定する診断部;
を含み、
前記癌は、肺癌、膵臓癌、胆道癌、乳癌、胃癌、脳腫瘍、腎臓癌、肝癌及び子宮頸部癌を含む固形癌のいずれか一つである、癌診断装置。 - 前記アシル-カルニチン(AC)は、ドデカノイル-L-カルニチン(DC)、ヘキサノイル-L-カルニチン(HC)、オクタノイル-L-カルニチン(OC)及びパルミトイル-L-カルニチン(PC)の少なくともいずれか一つを含むことを特徴とする請求項1に記載の癌診断装置。
- 前記リゾホスファチジルコリン(LPC)は、リゾホスファチジルコリン16:0(LPC16)及びリゾホスファチジルコリン18:0(LPC18)のいずれか一つを含むことを特徴とする請求項1に記載の癌診断装置。
- 前記診断部は、DC、HC、OC、PC、2PY、LPC16及びLPC18の少なくともいずれか一つの濃度に基づき、癌の診断情報を判定することを特徴とする請求項1に記載の癌診断装置。
- 前記診断部は、前記前処理された濃度を用いて四則演算を行うことによって、癌の診断情報を判定することを特徴とする請求項1に記載の癌診断装置。
- 前記濃度は、液体クロマトグラフ質量分析計(LC-MS)を通じて得られ、
前記質量分析計は、トリプルTOF、トリプル四極子及び定量性測定が可能なMALDI TOFのいずれか一つであることを特徴とする請求項1に記載の癌診断装置。 - 生物学的試料からDCの濃度を測定する濃度測定部;
前記測定された濃度を前処理する前処理部;及び
前記前処理された濃度を用いて線形判別分析を行うことによって、癌の診断情報を判定する診断部;
を含み、
前記癌は、膵臓癌、胆道癌、胃癌及び子宮頸部癌を含む固形癌のいずれか一つである、癌診断装置。 - 生物学的試料からDC、HC、OC及びPCの濃度を測定する濃度測定部;
前記測定された濃度を前処理する前処理部;並びに
前記前処理された濃度を用いて線形判別分析を行うことによって、癌の診断情報を判定する診断部;
を含み、
前記癌は、膵臓癌、胆道癌、胃癌及び子宮頸部癌を含む固形癌のいずれか一つである、癌診断装置。 - 生物学的試料からDCの濃度を測定する濃度測定部;
前記測定された濃度を前処理する前処理部;及び
前記前処理された濃度を用いて線形判別分析を行うことによって、癌の診断情報を判定する診断部;
を含み、
前記濃度測定部は、さらに2PY、LPC16及びLPC18の濃度を測定することを特徴とする癌診断装置。 - 前記診断部は、前記DC、HC、OC及びPCの濃度に基づき、癌の診断情報を判定することを特徴とする請求項8に記載の癌診断装置。
- 前記診断部は、前記前処理された濃度を用いて四則演算を行うことによって、癌の診断情報を判定することを特徴とする請求項7に記載の癌診断装置。
- 前記濃度は、液体クロマトグラフ質量分析計(LC-MS)を通じて得られ、
前記質量分析計は、トリプルTOF、トリプル四極子及び定量性測定が可能なMALDI TOFのいずれか一つであることを特徴とする請求項7に記載の癌診断装置。 - 生物学的試料からのACの濃度を用いて線形判別分析を行って癌診断のための情報を提供する方法であって、
前記癌は、膵臓癌、胆道癌、胃癌及び子宮頸部癌を含む固形癌のいずれか一つである、癌診断のための情報を提供する方法。 - 前記ACは、DC、HC、OC及びPCの少なくともいずれか一つを含むことを特徴とする請求項13に記載の癌診断のための情報を提供する方法。
- 前記線形判別分析は、さらに生物学的試料からの2PY及びLPCの濃度の少なくとも1つを用いて行われ、
前記LPCは、LPC16及びLPC18のいずれか一つを含むことを特徴とする請求項13に記載の癌診断のための情報を提供する方法。 - 前記濃度は、質量ピーク面積で生物学的試料を質量分析することによって得られることを特徴とする請求項13に記載の癌診断のための情報を提供する方法。
- 前記濃度は、液体クロマトグラフ質量分析計(LC-MS)を通じて得られ、
前記質量分析計は、トリプルTOF、トリプル四極子及び定量性測定が可能なMALDI TOFのいずれか一つであることを特徴とする請求項13に記載の癌診断のための情報を提供する方法。 - 生物学的試料から得られたAC、2PY及びLPCの少なくとも1つの濃度を用いた線形判別分析によって、癌診断のための情報を提供する方法であって、
生物学的試料からDC、HC、OC、PC、2PY、LPC16及びLPC18のそれぞれの濃度を得る工程;
前記測定された濃度を前処理する工程;及び
前記前処理したDCの濃度で行った線形判別分析の結果、前記前処理したDC、HC、OC及びPCの濃度で行った線形判別分析の結果、及び前記前処理したDC、HC、OC、PC、2PY、LPC16及びLPC18の濃度で行った線形判別分析の結果に基づいて癌を診断するための情報を提供する工程;
を含むことを特徴とする、癌診断のための情報を提供する方法。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20190037756 | 2019-04-01 | ||
KR10-2019-0037756 | 2019-04-01 | ||
KR10-2020-0024845 | 2020-02-28 | ||
KR1020200024845A KR102395558B1 (ko) | 2019-04-01 | 2020-02-28 | 고형암 진단 장치와 고형암 진단 정보 제공 방법 |
PCT/KR2020/003158 WO2020204373A2 (ko) | 2019-04-01 | 2020-03-06 | 고형암 진단 장치와 고형암 진단 정보 제공 방법 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2022531621A JP2022531621A (ja) | 2022-07-07 |
JP7401121B2 true JP7401121B2 (ja) | 2023-12-19 |
Family
ID=72666403
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2021572576A Active JP7401121B2 (ja) | 2019-04-01 | 2020-03-06 | 固形癌診断装置及び固形癌診断情報の提供方法 |
Country Status (6)
Country | Link |
---|---|
US (1) | US20220349895A1 (ja) |
EP (1) | EP4027139A4 (ja) |
JP (1) | JP7401121B2 (ja) |
KR (1) | KR20220062238A (ja) |
CN (1) | CN113939737A (ja) |
WO (1) | WO2020204373A2 (ja) |
Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006044680A1 (en) | 2004-10-14 | 2006-04-27 | The Cleveland Clinic Foundation | Methods of detecting colorectal cancer |
CN102680597A (zh) | 2012-05-08 | 2012-09-19 | 北京师范大学 | 区分结直肠腺瘤和结直肠癌的试剂盒 |
JP2013506142A (ja) | 2009-10-01 | 2013-02-21 | フェノメノーム ディスカバリーズ インク | 膵臓癌の血清ベースのバイオマーカー並びに疾患検出及び診断のためのその使用 |
JP2014533363A (ja) | 2011-11-11 | 2014-12-11 | メタボロン,インコーポレイテッド | 膀胱癌のバイオマーカーおよびそれを用いる方法 |
JP2015505965A (ja) | 2011-12-09 | 2015-02-26 | メタボロン,インコーポレイテッド | 腎癌のバイオマーカーおよびそれを用いる方法 |
WO2016038157A1 (en) | 2014-09-10 | 2016-03-17 | Idcgs Clínica De Diagnósticos Médicos Ltda | Biomarkers for assessing breast cancer |
JP2016511821A (ja) | 2012-01-03 | 2016-04-21 | ナショナル キャンサー センター | 癌診断装置 |
US20160266128A1 (en) | 2013-08-21 | 2016-09-15 | Ewha University-Industry Collaboration Foundation | Composition comprising lysophosphatidylcholine and homocysteic acid for ovarian cancer diagnosis and method using the same |
WO2017217669A1 (ko) | 2016-06-13 | 2017-12-21 | 국립암센터 | 담도암 진단 정보 제공 방법과 담도암 진단 장치 |
CN109239210A (zh) | 2018-09-10 | 2019-01-18 | 哈尔滨工业大学 | 一种胰腺导管腺癌标志物及其筛选方法 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6195147B2 (ja) * | 2013-03-18 | 2017-09-13 | 学校法人自治医科大学 | イソクエン酸脱水素酵素変異検出用マーカ |
KR101462206B1 (ko) * | 2013-06-26 | 2014-11-20 | 한국과학기술연구원 | 트립토판 대사 변화를 이용한 위암 진단용 기초 정보 제공 방법 |
CA3030219A1 (en) * | 2016-07-07 | 2018-01-11 | Berg Llc | Lipid, protein, and metabolite markers for the diagnosis and treatment of prostate cancer |
KR101937531B1 (ko) * | 2016-09-28 | 2019-01-10 | 국립암센터 | 대장암 진단 장치와 대장암 진단 정보 제공 방법 |
KR102003309B1 (ko) * | 2016-12-05 | 2019-07-25 | 한국과학기술연구원 | 대사체 및 임상지표를 활용한 관상동맥 심장질환 진단용 키트 및 기초 정보 제공 방법 |
-
2020
- 2020-03-06 WO PCT/KR2020/003158 patent/WO2020204373A2/ko unknown
- 2020-03-06 EP EP20782471.5A patent/EP4027139A4/en active Pending
- 2020-03-06 CN CN202080040771.7A patent/CN113939737A/zh active Pending
- 2020-03-06 JP JP2021572576A patent/JP7401121B2/ja active Active
- 2020-03-06 US US17/615,506 patent/US20220349895A1/en active Pending
-
2022
- 2022-04-27 KR KR1020220052054A patent/KR20220062238A/ko active Application Filing
Patent Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006044680A1 (en) | 2004-10-14 | 2006-04-27 | The Cleveland Clinic Foundation | Methods of detecting colorectal cancer |
JP2013506142A (ja) | 2009-10-01 | 2013-02-21 | フェノメノーム ディスカバリーズ インク | 膵臓癌の血清ベースのバイオマーカー並びに疾患検出及び診断のためのその使用 |
JP2014533363A (ja) | 2011-11-11 | 2014-12-11 | メタボロン,インコーポレイテッド | 膀胱癌のバイオマーカーおよびそれを用いる方法 |
JP2015505965A (ja) | 2011-12-09 | 2015-02-26 | メタボロン,インコーポレイテッド | 腎癌のバイオマーカーおよびそれを用いる方法 |
JP2016511821A (ja) | 2012-01-03 | 2016-04-21 | ナショナル キャンサー センター | 癌診断装置 |
CN102680597A (zh) | 2012-05-08 | 2012-09-19 | 北京师范大学 | 区分结直肠腺瘤和结直肠癌的试剂盒 |
US20160266128A1 (en) | 2013-08-21 | 2016-09-15 | Ewha University-Industry Collaboration Foundation | Composition comprising lysophosphatidylcholine and homocysteic acid for ovarian cancer diagnosis and method using the same |
WO2016038157A1 (en) | 2014-09-10 | 2016-03-17 | Idcgs Clínica De Diagnósticos Médicos Ltda | Biomarkers for assessing breast cancer |
WO2017217669A1 (ko) | 2016-06-13 | 2017-12-21 | 국립암센터 | 담도암 진단 정보 제공 방법과 담도암 진단 장치 |
CN109239210A (zh) | 2018-09-10 | 2019-01-18 | 哈尔滨工业大学 | 一种胰腺导管腺癌标志物及其筛选方法 |
Non-Patent Citations (7)
Title |
---|
Joanna Nizio et al.,Metabolomic study of human tissue and urine in clear cell renal carcinoma by LC-HRMS and PLS-DA,Analytical and Bioanalytical Chemistry,2018年,vol.410,pp.3859-3869,DOI: 10.1007/s00216-018-1059-x |
Junjun Ni et al.,Simultaneous determination of thirteen kinds of amino acid and eight kinds of acylcarnitine in human serum by LC-MS/MS and its application to measure the serum concentration of lung cancer patients,Biomed. Chromatogr.,2016年,vol.30,pp.1796-1806,DOI 10.1002/bmc.3755 |
NILUFER BAYRAKTAR et al.,The Relationship between Carnitine Levels and Lipid Peroxidation in Glial Brain Tumors,Turkish Journal of Medical Sciences,2008年,vol.38, no.4,pp.293-299 |
Xiao Luo et al.,Integration of metabolomic and transcriptomic data reveals metabolic pathway alteration in breast cancer and impact of related signature on survival,J Cell Physiol.,2018年12月17日,vol.234,pp.13021-13031.,DOI: 10.1002/jcp.27973 |
Xin Lu et al.,Metabolic profiling analysis upon acylcarnitines in tissues of hepatocellular carcinoma revealed the inhibited carnitine shuttle system caused by the downregulated carnitine palmitoyltransferase 2,Molecular Carcinogenesis,2018年,vol.58, no.5,pp.749-759,DOI: 10.1002/mc.22967 |
Yanhua Chen et al.,Development of a Data-Independent Targeted Metabolomics Method for Relative Quantification Using Liquid Chromatography Coupled with Tandem Mass Spectrometry,Anal. Chem.,2017年,vol.89,pp.6954-6962,DOI: 10.1021/acs.analchem.6b04727 |
Yingrong Chen et al.,Metabolomic profiling of human serum in lung cancer patients using liquid chromatography/hybrid quadrupole time-of-flight mass spectrometry and gas chromatography/mass spectrometry,J Cancer Res Clin Oncol,2015年,vol.141,pp.705-718,DOI 10.1007/s00432-014-1846-5 |
Also Published As
Publication number | Publication date |
---|---|
WO2020204373A2 (ko) | 2020-10-08 |
EP4027139A4 (en) | 2023-12-06 |
KR20220062238A (ko) | 2022-05-16 |
WO2020204373A3 (ko) | 2020-11-19 |
JP2022531621A (ja) | 2022-07-07 |
EP4027139A2 (en) | 2022-07-13 |
US20220349895A1 (en) | 2022-11-03 |
CN113939737A (zh) | 2022-01-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KLUPCZY—SKA et al. | Metabolomics in medical sciences ń trends, challenges and perspectives | |
Khamis et al. | Mass spectrometric based approaches in urine metabolomics and biomarker discovery | |
Jung et al. | Noninvasive diagnosis and evaluation of curative surgery for gastric cancer by using NMR-based metabolomic profiling | |
Wang et al. | Investigation and identification of potential biomarkers in human saliva for the early diagnosis of oral squamous cell carcinoma | |
Gowda et al. | Metabolomics-based methods for early disease diagnostics | |
Zhao et al. | UPLC-based metabonomic applications for discovering biomarkers of diseases in clinical chemistry | |
Hasim et al. | Revealing the metabonomic variation of EC using 1 H-NMR spectroscopy and its association with the clinicopathological characteristics | |
Mustafa et al. | Biomarker discovery for early detection of hepatocellular carcinoma in hepatitis C–infected patients | |
Davis et al. | Pancreatic ductal adenocarcinoma is associated with a distinct urinary metabolomic signature | |
KR102395558B1 (ko) | 고형암 진단 장치와 고형암 진단 정보 제공 방법 | |
Trifonova et al. | Postgenomics diagnostics: Metabolomics approaches to human blood profiling | |
Bu et al. | Metabolomics: a revolution for novel cancer marker identification | |
US20170023575A1 (en) | Identification of blood based metabolite biomarkers of pancreatic cancer | |
US10983127B2 (en) | Device for diagnosing colorectal cancer and method for providing colorectal cancer diagnosis information | |
US20150133331A1 (en) | Metabolite biomarkers for the detection of liver cancer | |
Cerrato et al. | Untargeted metabolomics of prostate cancer zwitterionic and positively charged compounds in urine | |
Manzi et al. | Improving diagnosis of genitourinary cancers: Biomarker discovery strategies through mass spectrometry-based metabolomics | |
Armitage et al. | Metabolomics of diet-related diseases using mass spectrometry | |
Kałużna-Czaplińska et al. | Current applications of chromatographic methods for diagnosis and identification of potential biomarkers in cancer | |
Ossoliński et al. | Targeted and untargeted urinary metabolic profiling of bladder cancer | |
Chen et al. | Targeting amine-and phenol-containing metabolites in urine by dansylation isotope labeling and liquid chromatography mass spectrometry for evaluation of bladder cancer biomarkers | |
JP7401121B2 (ja) | 固形癌診断装置及び固形癌診断情報の提供方法 | |
US20140162903A1 (en) | Metabolite Biomarkers For Forecasting The Outcome of Preoperative Chemotherapy For Breast Cancer Treatment | |
Li et al. | Serum metabolomic analysis of human upper urinary tract urothelial carcinoma | |
KR101552011B1 (ko) | 리소포스파티딜콜린 및 호모시스테인산을 포함하는 난소암 진단용 조성물 및 이를 사용하여 난소암을 진단하는 방법 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20211208 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20211208 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220603 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20221129 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20221206 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230301 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230620 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230919 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20231107 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20231130 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 7401121 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |